Advantest to Showcase Latest Test Solutions at SEMICON West 2025 in Phoenix, Ariz.

(TSE:6857),(TSE:6857.T), TOKYO, Oct. 06, 2025 (GLOBE NEWSWIRE) — Leading semiconductor test equipment supplier Advantest Corporation (TSE: 6857) will feature its latest semiconductor test solutions at SEMICON West 2025, which will be held from Oct. 7-9 at the Phoenix Convention Center in Phoenix, Ariz. Advantest will highlight its broad portfolio of leading-edge test technologies for applications, […]

Advantest to Showcase Latest Test Solutions at SEMICON West 2025 in Phoenix, Ariz.

Advantest to Showcase Latest Test Solutions at SEMICON West 2025 in Phoenix, Ariz. GlobeNewswire October 06, 2025 TOKYO, Oct. 06, 2025 (GLOBE NEWSWIRE) — Leading semiconductor test equipment supplier Advantest Corporation (TSE: 6857) will feature its latest semiconductor test solutions at SEMICON West 2025, which will be held from Oct. 7-9 at the Phoenix Convention

Olympus and W. L. Gore & Associates Enter into International Distribution Agreement to Expand the Olympus EndoTherapy Portfolio

Olympus Corporation, a global MedTech company committed to making people's lives healthier, safer and more fulfilling, has entered into an international distribution agreement with the medical products business of U.S.-based W. L. Gore & Associates, Inc. (hereinafter Gore), a global materials science company that develops innovative products across diverse industries. https://mma.prnewswire.com/media/2788798/GORE_VIABIL_Biliary_Endoprosthesis.jpg The agreement allows Olympus

LOG Pharma to Showcase Barrier Eco Packaging Powered by DOW HEALTH+ Polymers at CPHI Frankfurt 2025

LOG's sustainable barrier line combines performance and cost efficiency for protection against moisture and oxygen LOG Pharma Primary Packagingis joining forces with Dow, one of the world's leading materials science companies, to present LOG's innovative barrier eco lineat CPHI Frankfurt 2025, taking place on October 28-30. The barrier eco line, which will be displayed together

S.PELLEGRINO YOUNG CHEF ACADEMY ANNOUNCE THE WINNERS OF THE COLLATERAL AWARDS AHEAD OF THE GRAND FINALE 2024-25

The S.Pellegrino Young Chef Academy today unveiled the global winners of its three prestigious collateral awards, a significant milestone leading up to the Grand Finale of the 2024-25 Competition. These talented chefs, representing diverse regions, have distinguished themselves through an extensive selection process that began with local competitions across 15 regions worldwide. To view the

Onco3R Therapeutics Announces Completion of First Cohort in Phase 1 Trial of Novel SIK3 inhibitor O3R-5671 and Oral Presentation at UEGW 2025

Dosing of first cohort in Phase 1 trial of O3R-5671 complete with no adverse findings On track for full data read out in the first half of 2026 Discovery and preclinical data on O3R-5671 selected for oral presentation at United European Gastroenterology Week 2025 Leuven, Belgium. October 6, 2025. Onco3R Therapeutics, a clinical-stage immunology and

Opensignal launches suite of broadband capabilities to help ISPs optimize customer experience and gain competitive advantage

Broadband Spotlight and Broadband Focus products enable ISPs to benchmark their users' actual experience, not just the maximum potential of their networks Opensignal, the leading global provider of independent insights into consumers' connectivity experiences and choice of carrier, today announced a comprehensive suite of broadband capabilities designed to help Internet Service Providers (ISPs) enhance the

New SOM based on Renesas RZ/G3E processor offers ready-made platform for industrial systems with advanced HMI

The RZ/G3E SOM from Virtium Embedded Artists provides dual HD display outputs, 3D graphics and high-speed connectivity backed by two options for local AI processing Virtium Embedded Artists, a trusted designer and manufacturer of industrial and edge AI computing solutions, today released the RZ/G3E SOM, a system-on-module (SOM) based on the Renesas RZ/G3E application processor

Onco3R Therapeutics Announces Completion of First Cohort in Phase 1 Trial of Novel SIK3 inhibitor O3R-5671 and Oral Presentation at UEGW 2025

Onco3R Therapeutics Announces Completion of First Cohort in Phase 1 Trial of Novel SIK3 inhibitor O3R-5671 and Oral Presentation at UEGW 2025 GlobeNewswire October 06, 2025 Dosing of first cohort in Phase 1 trial of O3R-5671 complete with no adverse findings On track for full data read out in the first half of 2026 Discovery

U.S. Enterprise Fund for Ukraine (UMAEF) Invests in Fintech-IT Group, Powering it to a $1Bn Valuation as Ukraine’s First FinTech Unicorn

Ukraine-Moldova American Enterprise Fund (UMAEF, Fund) announces its investment in Fintech-IT Group, a leading developer of digital banking software in Ukraine, propelling the Company to a $1.0bn valuation in this growth equity round, achieving unicorn status and becoming the first FinTech unicorn out of Ukraine. UMAEF joins Fintech-IT Group founders Oleg Gorokhovskyi and Mykhaylo Rogalskyi,

Scroll to Top